We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF

134 hedge funds and large institutions have $411M invested in VanEck Pharmaceutical ETF in 2024 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 38 increasing their positions, 32 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

227% more call options, than puts

Call options by funds: $1.63M | Put options by funds: $499K

200% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 11

23% more funds holding

Funds holding: 109 → 134 (+25)

19% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 32

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

10.43% less ownership

Funds ownership: 86.67% → 76.24% (-10%)

29% less capital inflows, than outflows

Capital inflows: $46.9M | Capital outflows: $66.4M

Holders
134
Holders Change
+25
Holders Change %
+22.94%
% of All Funds
1.92%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
33
Increased
38
Reduced
32
Closed
11
Calls
$1.63​M
Puts
$499​K
Net Calls
+$1.13​M
Net Calls Change
+$4.11​M

PPH Hedge Fund Activity: Q1 2024 in Review

134 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2024, worth a combined $411M — up 7% from $384M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new PPH positions and 11 closed out — a net gain of 22 holders — while 38 added to existing stakes and 32 trimmed.

The largest buyer was J. Safra Asset Management, opening a new position worth an estimated $6.09M. The largest seller was Bank of America, cutting an estimated $19M.

  • 134 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2024, up from 109 in Q4 2023.
  • Funds reported $411M of VanEck Pharmaceutical ETF stock for Q1 2024, up 7% quarter-over-quarter.
  • 33 funds opened new VanEck Pharmaceutical ETF positions in Q1 2024 and 11 closed out, a net change of +22 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q1 2024 was J. Safra Asset Management, an estimated $6.09M added.
  • The largest VanEck Pharmaceutical ETF seller in Q1 2024 was Bank of America, an estimated $19M sold.

Based on aggregated 13F filings for Q1 2024.